1. Home
  2. CMU vs BMEA Comparison

CMU vs BMEA Comparison

Compare CMU & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

CMU

MFS Municipal Income Trust

N/A

Current Price

$3.65

Market Cap

90.0M

Sector

Finance

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.43

Market Cap

90.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CMU
BMEA
Founded
1987
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.0M
90.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CMU
BMEA
Price
$3.65
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
92.9K
804.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$52.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$0.87
52 Week High
$3.69
$3.08

Technical Indicators

Market Signals
Indicator
CMU
BMEA
Relative Strength Index (RSI) 60.11 57.44
Support Level $3.49 $1.24
Resistance Level N/A $1.56
Average True Range (ATR) 0.04 0.09
MACD 0.00 0.01
Stochastic Oscillator 68.79 70.37

Price Performance

Historical Comparison
CMU
BMEA

About CMU MFS Municipal Income Trust

Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: